![Joseph J. Hlavka](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joseph J. Hlavka
Corporate Officer/Principal chez Tetragenex Pharmaceuticals, Inc.
Profil
Joseph J.
Hlavka is currently the Director of Tetracycline Design & Synthesis at Tetragenex Pharmaceuticals, Inc. He obtained a doctorate degree from the Massachusetts Institute of Technology in 1957.
Postes actifs de Joseph J. Hlavka
Sociétés | Poste | Début |
---|---|---|
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | Corporate Officer/Principal | 05/02/2010 |
Formation de Joseph J. Hlavka
Massachusetts Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | Health Technology |